ABT — Abbott Laboratories Income Statement
0.000.00%
Last trade - 00:00
- $189.33bn
- $196.95bn
- $40.11bn
- 90
- 26
- 77
- 69
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 31,904 | 34,608 | 43,075 | 43,653 | 40,109 |
Cost of Revenue | |||||
Gross Profit | 18,708 | 19,641 | 24,585 | 24,570 | 22,190 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 27,435 | 29,136 | 34,650 | 35,336 | 33,670 |
Operating Profit | 4,469 | 5,472 | 8,425 | 8,317 | 6,439 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,077 | 4,968 | 8,211 | 8,306 | 6,664 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,601 | 4,497 | 7,071 | 6,933 | 5,723 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 3,687 | 4,495 | 7,071 | 6,933 | 5,723 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,687 | 4,495 | 7,071 | 6,933 | 5,723 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.12 | 2.5 | 4.03 | 4.12 | 3.43 |
Dividends per Share |